Search

everythinglearnresearchcommunity

for

Search:↓

User experienced rapid thinning on crown, used dutasteride for 3 months with significant improvement. Microneedling and ketoconazole were also used, but no minoxidil or finasteride.

The conversation discusses the potential of cinnamic acid for hair growth. It also mentions treatments like Minoxidil, finasteride, and RU58841.

PP405 shows promise in hair loss treatment, but stem cell therapy using adipose-derived stem cells and ATP also successfully reversed androgenetic alopecia in mice. Stem cell therapy is costly, and some doubt the effectiveness of PP405 based on press releases.

User restarted hair loss treatment with consistent finasteride, minoxidil, ketoconazole shampoo, and weekly dermarolling. Another user shared their regimen including dutasteride, oral minoxidil, RU58841, derma roller, ketoconazole shampoo, and stemoxydine.

AHK-Cu peptide is considered better than GHK-Cu for hair growth. The user is seeking recommendations for trusted AHK-Cu peptide brands with third-party testing.

Clascoterone (Breezula) showed positive results for treating hair loss without affecting cortisol levels. Opinions vary, with some users optimistic about its potential and others critical of its effectiveness compared to existing treatments like finasteride.

AMP-303, a new injectable treatment for androgenetic alopecia, showed promising results in increasing hair count and density with minimal side effects. The treatment demonstrated significant hair regrowth and durability, offering new hope for those with hair loss.

Hair cell therapy and follicle cloning are still in experimental stages, with treatments like hair multiplication and regenerative hair therapy being marketed but not yet proven to create unlimited new follicles. There is skepticism about the effectiveness and legitimacy of these treatments, with some considering them scams.

Winlevi (clascoterone 1%) is being discussed as a potential hair loss treatment. Users are considering its use despite concerns about its delivery method.

A potential non-invasive topical treatment targeting the WNT Signaling Pathway for hair regeneration is being researched, with positive results on human hair follicle cells. Current effective treatments for hair loss include Minoxidil, finasteride, and hair transplantation.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also inquires about the timeline for the GT20029 phase 3 trial by Kintor.

Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.

MCL-1 protein may help maintain hair follicles in the growth phase and prevent miniaturization. There is interest in experimental treatments like exosomes, peptides, or stem cell serums to upregulate MCL-1 for hair loss, especially for those not using minoxidil or finasteride.

The conversation discusses using topical cetirizine as a treatment for androgenetic alopecia (hair loss). Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

CRISPR Cas9 could potentially treat baldness by targeting specific genes in hair follicles without affecting other body functions. There is optimism about its future use, despite ethical concerns and the current reliance on treatments like minoxidil and finasteride.

The user saw no significant changes in hair loss after three months on 3mg Dutasteride, having previously used Finasteride and 0.5mg Dutasteride. They plan to continue the high dose for a year despite concerns about side effects and diminishing returns.

User asks if HMI 115 hasn't done phase 1 for AGA in humans. Conversation includes treatments Min, Fin, and RU.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

The conversation is about the approval of Clascoterone (Winlevi) in Canada for hair loss treatment. One user expressed skepticism about its effectiveness due to low concentration.

Clascoterone (CB) shows an excellent safety profile with no serious side effects, but its effectiveness may decline after six months, making it more suitable as an adjunct treatment with finasteride and minoxidil rather than a standalone solution. Some argue it could be better than finasteride due to its protection against testosterone, but its long-term efficacy remains debated.

BackToTheFutehair's 3.5 month progress update on their hair loss treatment regimen of finasteride, minoxidil, and microneedling which has led to a significant improvement in thickness and life to the hair. Others have provided encouragement and advice for future treatments.

Using finasteride and peptides, including GHK-Cu, improved hair thickness and regrowth. The user also used a KLOW blend and CJC/IPA for better sleep and recovery.

Clascoterone has shown promising results in increasing hair density without systemic side effects, potentially offering benefits similar to finasteride. There is skepticism due to the lack of published photos despite the market interest.

A 22-year-old used oral finasteride from Costco and topical Kirkland minoxidil for 4-5 months to treat hair loss, resulting in significant hair regrowth and restored confidence. The "big 3" refers to minoxidil, finasteride, and microneedling as hair loss treatments.

The conversation is about finding a reputable place to buy Clascoterone in the US. An alternative treatment, pyrilutamide, is suggested as a strong and official option.

The conversation is about when the phase 3 results for pyrilutamide, a potential hair loss treatment, will be released. There was a letter about the study a month ago, but the actual results were not included.

Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.

There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.

The conversation discusses hair loss treatments, with users mentioning dutasteride (Dut) as effective and wishing for more accessible dosages. They also debate the components of the "big 3" treatments, which now include Dut, RU58841, and oral minoxidil, with finasteride and minoxidil being consistently mentioned.

User reports being on finasteride for 3 months, experiencing initial shedding but noticing new hair growth and increased density. They also started using castor oil daily and considered trimming their long hair to improve visual thickness.